Dexmedetomidine

Brand names: Precedex
Drug class: Antineoplastic Agents , Antineoplastic Agents , Antineoplastic Agents

Usage of Dexmedetomidine

Sedation in Critical Care Settings

Sedation of initially intubated and mechanically ventilated patients in an intensive care setting (i.e., ICU).

May be used to provide mild to moderate levels of sedation, but not considered suitable for deep sedation.

FDA-labeled for use only for short-term (<24 hours) sedation; however, has been used for prolonged sedation† [off-label] in the intensive care setting. (See Tolerance and Tachyphylaxis under Cautions.)

Produces sedation, anxiolysis, and analgesia without causing significant respiratory depression.

Appears to be as effective as propofol and benzodiazepines (e.g., midazolam, lorazepam) for sedation in critically ill mechanically ventilated adults; however, because of some modest clinical benefits (e.g., reduced duration of mechanical ventilation, shorter time to extubation, reduced risk of delirium), nonbenzodiazepine sedatives (dexmedetomidine or propofol) are generally preferred to benzodiazepines.

When selecting an appropriate sedative agent, consider patient's individual sedation goals in addition to specific drug-related (e.g., pharmacology, pharmacokinetics, adverse effects, availability, costs) and patient-related (e.g., comorbid conditions such as anxiety, seizures, or alcohol or benzodiazepine withdrawal) factors.

Patients receiving dexmedetomidine are more arousable than those receiving other sedatives, which may be particularly useful for daily awakening trials.

Because dexmedetomidine does not have a substantial respiratory depressant effect, infusions of the drug can be continued following extubation, if needed.

Procedural Sedation

Sedation of nonintubated patients prior to and/or during surgical or other procedures.

Comparative efficacy with other sedative agents not established. May be preferred in certain patients (e.g., those in whom respiratory compromise with benzodiazepines is a concern); however, consider risks versus benefits.

Relate drugs

How to use Dexmedetomidine

General

  • Administer only by individuals experienced in the management of patients in an intensive care or surgical setting.
  • Individualize dosage and titrate to desired level of sedation.
  • Monitor patient continuously.

    • Administration

    IV Administration

    For solution and drug compatibility information, see Compatibility under Stability.

    Administer by IV infusion.

    May adsorb to some types of natural rubber; use administration components made with synthetic or coated natural rubber gaskets.

    Commercially available as an injection concentrate that must be diluted prior to IV infusion or as a premixed ready-to-use solution (dexmedetomidine hydrochloride in 0.9% sodium chloride injection).

    Dilution

    Must dilute the injection concentrate in 0.9% sodium chloride injection prior to administration. To prepare the 4-mcg/mL concentration used for loading and maintenance infusions, one method of dilution is to add 2 mL of the concentrate (100 mcg/mL) to 48 mL of 0.9% sodium chloride injection.

    Rate of Administration

    Administer by slow IV infusion via a controlled-infusion device.

    Rapid IV infusion associated with loss of α2-adrenergic selectivity and adverse cardiovascular effects. (See Actions and also see Cardiovascular Effects under Cautions.)

    Dosage

    Available as dexmedetomidine hydrochloride; dosage is expressed in terms of dexmedetomidine.

    Adults

    Sedation in Critical Care Settings IV

    Initiation of sedation: 1 mcg/kg as a loading infusion over 10 minutes. Because of risk of adverse hemodynamic effects, many clinicians do not recommend a loading dose; if a loading dose is used, caution is advised, particularly in patients with bradycardia, heart block, or hemodynamic instability. Manufacturer states loading dose may not be required in patients converting from an alternative sedative agent.

    Maintenance of sedation: Continuous IV infusion at a rate of 0.2–0.7 mcg/kg per hour recommended. Adjust infusion rate to desired level of sedation; in most cases, a light rather than deep level of sedation is recommended in critically ill, mechanically ventilated patients. Assess depth and quality of sedation using a validated and reliable assessment tool. Adjust dosage slowly to reduce risk of hypotension and other adverse effects.

    Evidence from clinical studies supports use of infusion rates up to 1.5 mcg/kg per hour.

    Manufacturer states that continuous IV infusion of dexmedetomidine should not exceed 24 hours. However, the drug has been used for prolonged (>24 hours) sedation in the ICU.

    Procedural Sedation IV

    Initiation of sedation: 1 mcg/kg as a loading infusion over 10 minutes. A loading infusion of 0.5 mcg/kg over 10 minutes may be suitable for less invasive procedures (e.g., ophthalmic surgery). For awake fiberoptic intubation, a loading infusion of 1 mcg/kg over 10 minutes is recommended.

    Maintenance of sedation: Initiate maintenance infusion at a rate of 0.6 mcg/kg per hour; adjust rate within range of 0.2–1 mcg/kg per hour to achieve desired level of sedation. For awake fiberoptic intubation in adults, a maintenance infusion of 0.7 mcg/kg per hour is recommended until endotracheal tube is secured.

    Special Populations

    Hepatic Impairment

    Consider dosage reduction.

    Renal Impairment

    Manufacturer makes no special dosage recommendations.

    Geriatric Patients

    For initiation and maintenance of ICU sedation in geriatric patients >65 years of age, consider dosage reduction.

    For procedural sedation in geriatric patients >65 years of age, reduce loading dose to 0.5 mcg/kg over 10 minutes; consider dosage reduction for maintenance of procedural sedation.

    Warnings

    Contraindications

  • None.

    • Warnings/Precautions

    Administration Precautions

    To minimize risk of adverse effects, follow recommendations for administration and monitoring of dexmedetomidine therapy. (See General under Dosage and Administration.)

    Cardiovascular Effects

    Bradycardia and sinus arrest reported in young, healthy adults with high vagal tone; also associated with other methods of administration, including rapid IV administration.

    Hypotension and/or bradycardia reported frequently; although intervention rarely required, some cases resulted in fatality. May be more pronounced in geriatric patients or those with hypovolemia, diabetes mellitus, or chronic hypertension. If treatment is required, consider slowing or stopping dexmedetomidine infusion, increasing IV fluids, elevating lower extremities, and/or use of vasopressors; consider IV anticholinergic agents (e.g., atropine sulfate, glycopyrrolate) to modify vagal tone. More advanced resuscitative measures may be necessary in patients with significant cardiovascular dysfunction.

    Transient hypertension reported with loading dose; treatment generally not required, although reduction in the loading dose infusion rate may be desirable.

    Supraventricular and ventricular tachycardia, atrial fibrillation, extrasystoles, and cardiac arrest reported during postmarketing experience.

    Use with caution in patients with (or at risk of) advanced heart block and/or severe ventricular dysfunction, and in patients receiving concomitant drugs that slow cardiac conduction.

    Withdrawal Effects

    Abrupt withdrawal of dexmedetomidine may result in clonidine-like withdrawal symptoms. Withdrawal-related events (e.g., nausea, vomiting, agitation, tachycardia, hypertension) reported following discontinuance of therapy in some patients after prolonged (up to 7 days) infusion for ICU sedation. Withdrawal symptoms not reported with short-term (<6 hours) infusions for procedural sedation.

    If tachycardia and/or hypertension occurs after discontinuance of dexmedetomidine, institute supportive therapy.

    Arousability

    Some patients observed to be arousable and alert when stimulated; should not be considered as evidence of lack of efficacy in the absence of other signs and symptoms.

    Tolerance and Tachyphylaxis

    Use of dexmedetomidine for durations >24 hours associated with tolerance, tachyphylaxis, and dose-related increase in adverse effects.

    Specific Populations

    Pregnancy

    Category C.

    No adequate and well-controlled studies in pregnant women. No evidence of teratogenicity in animal studies; however, fetal toxicity (e.g., postimplantation loss, reduced pup viability, reduced pup weight) observed.

    Use during pregnancy only when potential benefits justify potential risks to fetus.

    Lactation

    Distributed into milk in rats; not known whether distributed into human milk. Caution if used in nursing women.

    Pediatric Use

    Manufacturer states safety and efficacy not established in pediatric patients <18 years of age. However, the drug has been used in pediatric patients undergoing sedation in the ICU or other settings to facilitate mechanical ventilation or other procedures (e.g., radiologic imaging). Additional study is needed to evaluate the drug's safety in this population.

    Geriatric Use

    Hypotension and/or bradycardia may be more pronounced. Consider dosage reduction. (See Geriatric Patients under Dosage and Administration.)

    Renal Impairment

    Pharmacokinetics in patients with severe renal impairment (Clcr <30 mL/minute) and healthy individuals are similar.

    Hepatic Impairment

    Clearance may be reduced. Consider dosage reduction. (See Hepatic Impairment under Dosage and Administration.)

    Common Adverse Effects

    Short-term (<24 hours) infusions for ICU sedation: Hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypovolemia, atelectasis, atrial fibrillation, hypoxia, tachycardia, hemorrhage, anemia, dry mouth.

    Long-term (>24 hours) infusions for ICU sedation: Hypotension, bradycardia, hypertension, tachycardia, hypokalemia, agitation, hyperglycemia, constipation, hypoglycemia, respiratory failure.

    Procedural sedation: Hypotension, respiratory depression, bradycardia, hypertension, tachycardia, nausea, dry mouth.

    What other drugs will affect Dexmedetomidine

    Metabolized by CYP isoenzymes, principally CYP2A6. However, no evidence of clinically important CYP-mediated drug interactions in vitro.

    Drugs with Negative Chronotropic Effects

    Potential pharmacodynamic interaction (additive pharmacodynamic effects). Use with caution.

    Protein-bound Drugs

    Pharmacokinetic interaction unlikely.

    Specific Drugs

    Drug

    Interaction

    Comments

    Anesthetics

    Additive pharmacologic effects

    May require reduction in dosage of dexmedetomidine or concomitant drug

    Digoxin

    Negligible change in dexmedetomidine protein binding in vitro; negligible displacement of digoxin from protein binding sites in vitro

    Possible additive hypotensive and bradycardic effects

    Caution is advised

    Fentanyl

    Negligible change in dexmedetomidine protein binding in vitro

    Ibuprofen

    Negligible displacement of ibuprofen from protein binding sites in vitro

    Ketorolac

    Negligible change in dexmedetomidine protein binding in vitro

    Lidocaine

    Negligible change in dexmedetomidine protein binding in vitro

    Neuromuscular blocking agents

    Increased plasma rocuronium concentrations

    No clinically important effect on neuromuscular blockade

    Opiate agonists

    Additive pharmacologic effects

    May require reduction in dosage of dexmedetomidine or concomitant drug

    Phenytoin

    Negligible displacement of phenytoin from protein binding sites in vitro

    Propranolol

    Negligible displacement of propranolol from protein binding sites in vitro

    Sedatives/hypnotics

    Additive pharmacologic effects

    May require reduction in dosage of dexmedetomidine or concomitant drug

    Theophylline

    Negligible change in dexmedetomidine protein binding in vitro; negligible displacement of theophylline from protein binding sites in vitro

    Vasodilators

    Possible additive hypotensive effects

    Use with caution

    Warfarin

    Negligible displacement of warfarin from protein binding sites in vitro

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords